We have located links that may give you full text access.
[Dalbavancin breakpoints and recommendations for in vitro study of its activity].
Enfermedades Infecciosas y Microbiología Clínica 2017 January
Dalbavancin is a semisynthetic lipoglycopeptide approved for the treatment of acute skin and soft tissue infections due to Gram-positive microorganisms susceptible to this antimicrobial agent. The FDA (Food and Drug Administration) and the EUCAST (European Committee on Antimicrobial Susceptibility Testing) have established clinical breakpoints to interpret the results of the antibiogram (expressed as MIC [minimum inhibitory concentration]) with approved doses (1g intravenously [IV] followed by 0.5g IV at day 8 or 1.5g IV in a single dose). The EUCAST has also determined PK/PD (pharmacokinetic/pharmacodynamic) breakpoints -susceptible, ≤ 0.25mg/L; resistant, > 0.25mg/L-, established recommendations for in vitro susceptibility testing (addition of polysorbate-80 to the growth media) and subrogate values based on the vancomycin-susceptible category to interpret dalbavancin susceptibility in the absence of in vitro study of this antimicrobial.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app